Lantern Pharma Files 8-K with Corporate Updates
Ticker: LTRN · Form: 8-K · Filed: May 24, 2024 · CIK: 1763950
| Field | Detail |
|---|---|
| Company | Lantern Pharma Inc. (LTRN) |
| Form Type | 8-K |
| Filed Date | May 24, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, financials, sec-filing
TL;DR
Lantern Pharma filed an 8-K on 5/23 for corporate updates and financials.
AI Summary
Lantern Pharma Inc. filed an 8-K on May 23, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, incorporated in Delaware with its principal executive offices in Dallas, Texas, operates in the pharmaceutical preparations industry.
Why It Matters
This filing indicates routine corporate actions and financial reporting, providing transparency to investors about the company's administrative and financial status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for corporate updates and financial reporting, not indicating any immediate material changes or risks.
Key Numbers
- 001-39318 — SEC File Number (Identifies the company's filing with the SEC.)
- 46-3973463 — IRS Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- Lantern Pharma Inc. (company) — Registrant
- May 23, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Dallas, Texas (location) — Address of principal executive offices
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What specific amendments were made to Lantern Pharma Inc.'s articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the excerpt.
What is the primary business of Lantern Pharma Inc. according to the filing?
Lantern Pharma Inc. is classified under Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated May 23, 2024.
Where are Lantern Pharma Inc.'s principal executive offices located?
The principal executive offices are located at 1920 McKinney Avenue, 7th Floor, Dallas, Texas 75201.
What is the SEC file number for Lantern Pharma Inc.?
The SEC file number for Lantern Pharma Inc. is 001-39318.
Filing Stats: 559 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-05-24 16:09:39
Key Financial Figures
- $0.0001 — ch registered Common stock: Par value $0.0001 LTRN Nasdaq Capital Market Item
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex3-2.htm (EX-3.2) — 3KB
- 0001493152-24-021353.txt ( ) — 217KB
- ltrn-20240523.xsd (EX-101.SCH) — 3KB
- ltrn-20240523_lab.xml (EX-101.LAB) — 33KB
- ltrn-20240523_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LANTERN PHARMA INC. Dated: May 24, 2024 /s/ David Margrave David Margrave, Chief Financial Officer